Skip to main content

Table 3 Unadjusted and adjusted association with dual therapy discontinuation by any cause (Cox proportional Hazard Model)

From: Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study

  Unadjusted HR (95 % CI) Adjusted HR (95 % CI) P value
Male gender 1.08 (0.63–1.86) 1.12 (0.65–1.92) n.s.
Age (by year) 1.09 (0.98–1.02) 1.00 (0.97–1.03) n.s.
Non-Italian origin 0.45 (0.17–1.24) 0.43 (0.15–1.24) n.s.
Years on cART (each) 0.97 (0.94–1.01) 0.94 (0.89–1.00) 0.033
IDU as risk factor 1.02 (0.93–1.12) 1.01 (0.91–1.11) n.s.
AIDS diagnosis 1.19 (0.75–1.89) 0.84 (0.49–1.44) n.s.
No. of previous regimens (per each one more) 1.04 (1.00–1.09) 1.10 (1.01–1.13) 0.027
CD4 nadir (by 50) 1.37 (0.84–2.21) 1.43 (0.81–2.52) n.s.
<200 /mmc Baseline CD4 count 2.07 (1.19–3.60) 2.18 (1.18–4.03) 0.013
HCV coinfection 0.99 (0.61–1.60) 1.26 (0.75–2.11) n.s.
Previous virological failure 0.89 (0.55–1.42) 1.14 (0.95–1.38) n.s.
Switch to (PI/r)
 ATV/r 0.79 (0.41–1.49) 0.29 (0.09–0.99) 0.049
 DRV/r 0.61 (0.39–0.96) 0.21 (0.07–0.63) 0.005
 LPV/r 2.06 (1.25–3.42) 0.46 (0.14–1.50) n.s.
Switch to (Second Drug)
 ETR 1.41 (0.83–2.40) 0.62 (0.23–1.68) n.s.
 RAL 0.67 (0.43–1.05) 0.37 (0.13–1.04) n.s.
 MVC 0.74 (0.34–1.62) 0.49 (0.15–1.62) n.s.
 3TC 1.66 (0.62–3.84) 0.65 (0.18–2.39) n.s.
 TDF 1.39 (0.67–2.91) 0.59 (0.18–1.93) n.s.